Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Board Member Added 20,000 Shares of Gilead

We can compare Gilead to GlaxoSmithKline plc (NYSE:GSK), Pfizer Inc. (NYSE:PFE), Abbott Laboratories (NYSE:ABT), and Bristol-Myers Squibb Co. (NYSE:BMY). The trailing earnings multiples at these peers are generally at 15 or lower, which make for considerable discounts to where Gilead trades. The exception is Bristol-Myers Squibb, which trades at 32 times trailing earnings. On a forward basis analysts expect it to grow a bit more quickly than Gilead, pulling the two stocks roughly even in terms of forward earnings multiples. We’d also note that earnings growth is expected to be lower at the other companies- and even negative at Abbott- so in terms of 2014 the valuation range narrows considerably (though of course that is dependent on Gilead hitting its earnings targets for the next couple years). Abbott is the only one of these four peers to report an increase in revenue in its most recent quarter compared to the same period in the previous year, and even there net income was down over 30%.

Certainly Gilead has an advantage over these other companies in that its business is stable, let alone growing nicely. The valuation is high, and certainly does depend on continued earnings growth at least at a similar level to what the company has been doing, and so even with the large insider purchase we would be hesitant to buy here. Perhaps it might be wise to look for specific drugs that should drive earnings growth or come back to the stock after the next quarterly report.

Disclosure: I own no shares of any stocks mentioned in this article.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.